These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37927492)

  • 1. Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast].
    Cohen SB; Leach MZ
    Open Access Rheumatol; 2023; 15():207-212. PubMed ID: 37927492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
    Huizinga TWJ; Torii Y; Muniz R
    Rheumatol Ther; 2021 Mar; 8(1):41-61. PubMed ID: 33263165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X; Hu R; Peng L; Liu M; Sun Z
    Front Immunol; 2021; 12():638444. PubMed ID: 33889152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M; Fiorino G; Gilardi D; Furfaro F; Roda G; Loy L; Allocca M; Peyrin-Biroulet L; Danese S
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis.
    Kovitwanichkanont T; Raghunath S; Wang D; Kyi L; Pignataro S; Morton S; Morand E; Leech M
    Intern Med J; 2020 Mar; 50(3):374-377. PubMed ID: 32141205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
    Cisek S; Choi D; Stubbings J; Bhat S
    Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humira: the impending patent battles over adalimumab biosimilars.
    Norman P
    Pharm Pat Anal; 2016 May; 5(3):141-5. PubMed ID: 27087201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Biosimilars of Adalimumab.
    Kaushik VV
    J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plain language summary of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis.
    Cohen SB; Lee EC
    Immunotherapy; 2022 Oct; 14(15):1183-1190. PubMed ID: 36065786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
    Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
    Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.